Physician profile
Lisa Moore
NPI 1265993695
$2,131.76
in general payments reported to CMS, 2019-2025
19 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $206 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.77 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.40 | 2024-2025 | |
| Pfizer INC. | $352.23 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $146.67 | 2025 | |
| Lundbeck LLC | $133.44 | 2024-2025 | Vyepti |
| Axsome Therapeutics, INC. | $129.13 | 2025 | Symbravo |
| Biogen, INC. | $106.33 | 2025 | |
| Amgen INC. | $85.99 | 2025 | Uplizna |
| Argenx US, INC. | $77.37 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $73.41 | 2025 | Valtoco |
| Eisai INC. | $56.13 | 2025 | |
| Novartis Pharmaceuticals Corporation | $53.55 | 2025 | |
| Merz Pharmaceuticals, LLC | $48.82 | 2025 | Xeomin, Inbrija, Ampyra |
| Livanova USA, INC. | $44.33 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Vanda Pharmaceuticals INC. | $36.79 | 2024 | Ponvory |
| Abbott Laboratories | $34.19 | 2025 | Infinity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $33.57 | 2025 | Crexont |
| Alexion Pharmaceuticals, INC. | $27.18 | 2025 | Ultomiris |
| Emd Serono, INC. | $23.54 | 2025 | |
| Lilly USA, LLC | $19.69 | 2024 | Emgality, Reyvow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.